Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Panel Clears KalVista’s HAE Drug, GSK’s Asthma Agent, and More for Approval
A Japanese health ministry panel on November 27 endorsed approvals for seven new molecular entities (NMEs) — including KalVista Pharmaceuticals’ on-demand hereditary angioedema (HAE) therapy sebetralstat, known overseas as Ekterly. The Pharmaceutical Affairs Council’s Second Committee on Drugs backed sebetralstat,…
To read the full story
Related Article
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Nipro-Samsung Alliance Nears First Approval in Japan with Stelara Biosimilar
November 14, 2025
- Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
November 14, 2025
- Tecentriq Filed for Thymic Carcinoma in Japan: Chugai
May 15, 2025
- Nippon Shinyaku Files BPDCN Drug in Japan
March 31, 2025
- Sanofi Japan Files Dupixent for Asthma in Children Aged 6-11
February 12, 2025
- GSK Files Depemokimab for Asthma and CRSwNP in Japan
January 29, 2025
- KalVista Files HAE Drug Sebetralstat in Japan
January 29, 2025
REGULATORY
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…